Sara Fancelli

590 total citations
25 papers, 302 citations indexed

About

Sara Fancelli is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Sara Fancelli has authored 25 papers receiving a total of 302 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 14 papers in Pulmonary and Respiratory Medicine and 4 papers in Molecular Biology. Recurrent topics in Sara Fancelli's work include Cancer Immunotherapy and Biomarkers (6 papers), Colorectal Cancer Treatments and Studies (5 papers) and Lung Cancer Treatments and Mutations (5 papers). Sara Fancelli is often cited by papers focused on Cancer Immunotherapy and Biomarkers (6 papers), Colorectal Cancer Treatments and Studies (5 papers) and Lung Cancer Treatments and Mutations (5 papers). Sara Fancelli collaborates with scholars based in Italy, Spain and Germany. Sara Fancelli's co-authors include Enrico Caliman, Serena Pillozzi, Lorenzo Antonuzzo, Francesca Mazzoni, Luca Voltolini, Niki Karachaliou, Daniele Lavacchi, Peng Cao, Andrés F. Cardona and Imane Chaib and has published in prestigious journals such as Journal of Clinical Oncology, Scientific Reports and International Journal of Molecular Sciences.

In The Last Decade

Sara Fancelli

25 papers receiving 296 citations

Peers

Countries citing papers authored by Sara Fancelli

Since Specialization

Citations

This map shows the geographic impact of Sara Fancelli's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sara Fancelli with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sara Fancelli more than expected).

Fields of papers citing papers by Sara Fancelli

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sara Fancelli. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sara Fancelli. The network helps show where Sara Fancelli may publish in the future.

Co-authorship network of co-authors of Sara Fancelli

This figure shows the co-authorship network connecting the top 25 collaborators of Sara Fancelli. A scholar is included among the top collaborators of Sara Fancelli based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sara Fancelli. Sara Fancelli is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Unconventional strategy could be the future: From target to KRAS broad range treatment 2024 ·Heliyon ·Sara Fancelli, Giulia Petroni, Serena Pillozzi, Lorenzo Antonuzzo	1
2	Pathological complete response achieved with FLOT chemotherapy in two patients with MSI-H esophagogastric junction and gastric adenocarcinoma 2024 ·Anti-Cancer Drugs ·(unknown), Daniele Lavacchi, Luca Messerini, Vittorio Briganti, Franca Castiglione, Marco Brugia, Valentina Berti, Sara Fancelli, Fabio Cianchi, (unknown), Serena Pillozzi, Lorenzo Antonuzzo	1
3	Impact of natremia on metastatic non small cell lung cancer patients receiving immune checkpoint inhibitors 2024 ·Scientific Reports ·M. Catalano, Sara Fancelli, Enrico Caliman, Francesca Mazzoni, Maud Michelet, Silvia Mancini, (unknown), (unknown), (unknown), Serena Pillozzi, Lorenzo Antonuzzo, Giandomenico Roviello	4
4	Perioperative Tailored Treatments for Gastric Cancer: Times Are Changing 2023 ·International Journal of Molecular Sciences ·Daniele Lavacchi, Sara Fancelli, (unknown), (unknown), (unknown), (unknown), Enrico Caliman, (unknown), Elisa Giommoni, Marco Brugia, Fabio Cianchi, Serena Pillozzi, Giandomenico Roviello, Lorenzo Antonuzzo	11
5	Eosinophil count and immune-related adverse events (irAEs) as predictive biomarkers of survival in patients with NSCLC treated with ICIs. 2023 ·Journal of Clinical Oncology ·Elisa Giommoni, Serena Pillozzi, (unknown), (unknown), Enrico Caliman, Francesca Mazzoni, Sara Fancelli, Daniele Lavacchi, Marco Brugia, Elisa Pellegrini, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Lorenzo Antonuzzo	1
6	Alteration of the Nucleotide Excision Repair (NER) Pathway in Soft Tissue Sarcoma 2022 ·International Journal of Molecular Sciences ·(unknown), (unknown), Domenico Andrea Campanacci, Guido Scoccianti, Andrea Bernini, Daniela Grasso, Elisabetta Gambale, (unknown), Ilaria Palchetti, Annarita Palomba, Sara Fancelli, Enrico Caliman, Lorenzo Antonuzzo, Serena Pillozzi	8
7	Gender Matters. Sex-related Differences in Immunotherapy Outcome in Patients with Non-small Cell Lung Cancer 2022 ·Current Cancer Drug Targets ·Enrico Caliman, (unknown), (unknown), Francesca Mazzoni, (unknown), Sara Fancelli, Luca Paglialunga, Camilla Comin, Giandomenico Roviello, Serena Pillozzi, Lorenzo Antonuzzo	5
8	Absolute eosinophil count predicts clinical outcomes and toxicity in non-small cell lung cancer patients treated with immunotherapy 2022 ·Cancer Treatment and Research Communications ·Enrico Caliman, Sara Fancelli, (unknown), Francesca Mazzoni, Luca Paglialunga, Daniele Lavacchi, (unknown), Elisa Giommoni, (unknown), (unknown), Luca Voltolini, Camilla Comin, Serena Pillozzi, Lorenzo Antonuzzo	17
9	Mutations matter: An observational study of the prognostic and predictive value of KRAS mutations in metastatic colorectal cancer 2022 ·Frontiers in Oncology ·Daniele Lavacchi, Sara Fancelli, Giandomenico Roviello, Franca Castiglione, Enrico Caliman, Gemma Rossi, (unknown), Elisa Pellegrini, Marco Brugia, (unknown), (unknown), Fabio Cianchi, Serena Pillozzi, Lorenzo Antonuzzo	16
10	Challenges in the treatment of small cell lung cancer in the era of immunotherapy and molecular classification 2022 ·Lung Cancer ·Enrico Caliman, Sara Fancelli, Giulia Petroni, (unknown), (unknown), (unknown), Francesca Mazzoni, Luca Voltolini, Serena Pillozzi, Lorenzo Antonuzzo	26
11	Ivosidenib in IDH1-mutated cholangiocarcinoma: Clinical evaluation and future directions 2022 ·Pharmacology & Therapeutics ·Daniele Lavacchi, Enrico Caliman, Gemma Rossi, (unknown), (unknown), Sara Fancelli, Elisa Pellegrini, Giandomenico Roviello, Serena Pillozzi, Lorenzo Antonuzzo	18
12	KRAS G12 isoforms exert influence over up-front treatments: A retrospective, multicenter, Italian analysis of the impact of first-line immune checkpoint inhibitors in an NSCLC real-life population 2022 ·Frontiers in Oncology ·Sara Fancelli, Enrico Caliman, Francesca Mazzoni, Luca Paglialunga, (unknown), Daniele Lavacchi, Rossana Berardi, Giulia Mentrasti, Giulio Metro, (unknown), Angelo Delmonte, (unknown), Camilla Comin, Franca Castiglione, (unknown), Luca Voltolini, Serena Pillozzi, Lorenzo Antonuzzo	5
13	Chasing the Target: New Phenomena of Resistance to Novel Selective RET Inhibitors in Lung Cancer. Updated Evidence and Future Perspectives 2021 ·Cancers ·Sara Fancelli, Enrico Caliman, Francesca Mazzoni, Marco Brugia, Franca Castiglione, Luca Voltolini, Serena Pillozzi, Lorenzo Antonuzzo	29
14	TAS-102 in gastric cancer: Development and perspectives of a new biochemically modulated fluroropyrimidine drug combination 2020 ·Critical Reviews in Oncology/Hematology ·Giandomenico Roviello, Sara Fancelli, (unknown), Giuseppe Aprile, Stefania Nobili, Franco Roviello, Fabio Cianchi, Enrico Mini, Daniele Lavacchi	8
15	A case report of eyelid Merkel cell carcinoma occurring under treatment with nivolumab for a lung adenocarcinoma 2018 ·BMC Cancer ·Daniele Lavacchi, Stefania Nobili, Marco Brugia, (unknown), Sara Fancelli, Enrico Caliman, Federica Vergoni, Enrico Mini	3
16	Patterns of Care and Clinical Outcomes of HER2-positive Metastatic Breast Cancer Patients With Newly Diagnosed Stage IV or Recurrent Disease Undergoing First-line Trastuzumab-based Therapy: A Multicenter Retrospective Cohort Study 2017 ·Clinical Breast Cancer ·Matteo Lambertini, Arlindo R. Ferreira, Antonio Di Meglio, Francesca Poggio, Fabio Puglisi, Federico Sottotetti, Filippo Montemurro, Elena Poletto, Antônio Bernardo, Emanuela Risi, Chiara Dellepiane, Valentina Sini, Gabriele Minuti, Donatella Grasso, Sara Fancelli, Lucia Del Mastro	25
17	T-DM1 for HER2 positive advanced breast cancer: a single institution, “real life” experience 2015 ·Annals of Oncology ·Ilaria Bertolini, (unknown), Sara Fancelli, Claudia De Angelis, (unknown), (unknown), Elisabetta Landucci, Andrea Michelotti, Alfredo Falcone	1
18	Incremental value of 3D echocardiography and two-dimensional speckle tracking in the early detection of cardiotoxicity linked to chemotherapy and trastuzumab in patients with HER-2 positive breast cancer 2015 ·Annals of Oncology ·(unknown), Iacopo Fabiani, Nicola Riccardo Pugliese, Claudia De Angelis, Ilaria Bertolini, (unknown), Sara Fancelli, Andrea Fontana, B Salvadori, Elisa Landucci, Andrea Michelotti, Alfredo Falcone, Vitantonio Di Bello	1
19	Inherited mutations in breast cancer susceptibility genes among a triple negative breast cancer cohort unselected for family history of breast cancer 2015 ·Annals of Oncology ·B. Salvadori, Maria A. Caligo, (unknown), (unknown), Andrea Fontana, Elisabetta Landucci, (unknown), (unknown), Ilaria Bertolini, Claudia De Angelis, Sara Fancelli, E. Pfanner, Alfredo Falcone	1
20	Reducing radiological imaging during post-operative monitoring of breast cancer patients with serum CEA-TPA-CA15.3 tumor marker (TM) panel and an individual reference limit (IRL) 2012 ·CINECA IRIS Institutial research information system (University of Pisa) ·Andrea Nicolini, Sara Fancelli, Paola Ferrari, L Anselmi	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact